Trial IRCT20190810044500N7
Publication Roostaei A, BMC Infect Dis (2021) (published paper)
Dates: 2020-04-12 to 2020-08-02
Funding: Public/non profit (Research and Technology Department of Shahid Sadoughi University of Medical Science)
Conflict of interest: No
Methods | |
RCT Blinding: | |
Location :
Single center / Iran Follow-up duration (days): 14 | |
Inclusion criteria |
|
Exclusion criteria |
|
Interventions | |
Treatment
Levamisole 50 mg orally three times daily for 3 days |
|
Control
Placebo | |
Participants | |
Randomized participants : Levamisole=27 Placebo=25 | |
Characteristics of participants N= 52 Mean age : NR 30 males Severity : Mild: n= 50/ Asymptomatic: n=0 Number of vaccinated participants: NR | |
Primary outcome | |
In the register Clinical symptoms include fever, cough, shortness of breath | |
In the report NR | |
Documents available |
Protocol NR Statistical plan NR Data-sharing willing stated in the publication: Not reported |
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Some concerns |
General comment | In addition to the pre-print article the trial registy was used in data extraction and risk of bias assessment. Neither protocol nor statistical analysis plan was available. There were no substantive differences between the trial registry and pre-print article in population, procedures, interventions or outcomes. This study was updated on April 06th, 2021, with data from the published report. |